TAKEDA PHARMACEUTICAL COMPANY LIMITED Onderneming Takeda Pharmaceutical Company Limited Börse Stuttgart
Aandelen
TKD
JP3463000004
Farmaceutische producten
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 23,45 EUR | -1,18% |
|
-3,42% | -9,18% |
Vakgebied
- verkoop van geneesmiddelen en consumentenverzorgingsproducten;
- diensten.
De netto-omzet is geografisch als volgt verdeeld: Japan (17,5%), Azië (5%), de Verenigde Staten (49%), Europa en Canada (20,8%), Latijns-Amerika (3,8%), Rusland en GOS (1,8%) en overige (2,1%).
Verkoop per activiteit
| JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Gastroenterology - Entyvio
17,4
%
| 521 778 | 14,6 % | 702 744 | 17,4 % | +34,68% |
Plasma-derived Therapies - Immunoglobulin
13,0
%
| 385 864 | 10,8 % | 522 211 | 13,0 % | +35,34% |
Neuroscience - Vyvanse/Elvanse
11,4
%
| 327 052 | 9,2 % | 459 289 | 11,4 % | +40,43% |
Other - Others
9,1
%
| 515 164 | 14,4 % | 364 968 | 9,1 % | -29,15% |
Rare Genetic Diseases and Others - Tacxiro
3,8
%
| - | - | 151 800 | 3,8 % | - |
Plasma-derived Therapies - Albumin
3,0
%
| 90 035 | 2,5 % | 121 446 | 3,0 % | +34,89% |
Rare Blood Disease - advertise
2,9
%
| 118 491 | 3,3 % | 118 188 | 2,9 % | -0,26% |
Oncology - Leuplin/Enantone
2,8
%
| 106 459 | 3,0 % | 111 311 | 2,8 % | +4,56% |
Gastroenterology - Takecab-f
2,7
%
| 102 397 | 2,9 % | 108 719 | 2,7 % | +6,17% |
Neuroscience - Trintelix
2,5
%
| 82 315 | 2,3 % | 100 081 | 2,5 % | +21,58% |
Gastroenterology - Gattex/Revestive
2,3
%
| 75 751 | 2,1 % | 93 076 | 2,3 % | +22,87% |
Oncology - Ninlaro
2,3
%
| 91 203 | 2,6 % | 92 691 | 2,3 % | +1,63% |
Rare Genetic Diseases and Others - Ella Place
2,1
%
| 73 119 | 2,0 % | 85 321 | 2,1 % | +16,69% |
Oncology - Adcetris
2,1
%
| 69 190 | 1,9 % | 83 937 | 2,1 % | +21,31% |
Neuroscience - Others
1,9
%
| 72 926 | 2,0 % | 78 341 | 1,9 % | +7,43% |
Other - Azilva
1,8
%
| 76 297 | 2,1 % | 72 897 | 1,8 % | -4,46% |
Gastroenterology - Others
1,8
%
| 82 877 | 2,3 % | 72 388 | 1,8 % | -12,66% |
Gastroenterology - Dexilant
1,7
%
| 50 763 | 1,4 % | 69 371 | 1,7 % | +36,66% |
Rare Genetic Diseases and Others - Replagal
1,7
%
| 51 714 | 1,4 % | 66 741 | 1,7 % | +29,06% |
Rare Blood Disease - Adynovate/Advynovi
1,7
%
| 60 726 | 1,7 % | 66 553 | 1,7 % | +9,60% |
Rare Genetic Diseases and Others - Others
1,4
%
| - | - | 55 989 | 1,4 % | - |
Oncology - Others
1,3
%
| 43 329 | 1,2 % | 51 551 | 1,3 % | +18,98% |
Rare Genetic Diseases and Others - Biprib
1,2
%
| 42 408 | 1,2 % | 48 372 | 1,2 % | +14,06% |
Oncology - Iclusig
1,2
%
| 34 860 | 1,0 % | 47 206 | 1,2 % | +35,42% |
Rare Blood Disease - Other
1,2
%
| 53 013 | 1,5 % | 46 367 | 1,2 % | -12,54% |
Gastroenterology - Pantoloc/Controloc
1,1
%
| 40 275 | 1,1 % | 45 518 | 1,1 % | +13,02% |
Rare Blood Disease - Fiber
1,0
%
| 39 162 | 1,1 % | 41 268 | 1,0 % | +5,38% |
Plasma - Derived Immune Disease Treatment - Other
0,9
%
| 31 052 | 0,9 % | 34 786 | 0,9 % | +12,02% |
Oncology - Velcade
0,7
%
| 110 046 | 3,1 % | 27 759 | 0,7 % | -74,78% |
Oncology - Arumbrig
0,5
%
| 13 644 | 0,4 % | 20 556 | 0,5 % | +50,66% |
Rare Blood Disease - Hemofil/Immunate/Immunine
0,5
%
| - | - | 19 581 | 0,5 % | - |
Other - Rotrigger
0,4
%
| 32 690 | 0,9 % | 16 732 | 0,4 % | -48,82% |
Rare Hematology - Recombinate
0,3
%
| 12 297 | 0,3 % | 12 762 | 0,3 % | +3,78% |
Rare Genetic Diseases and Others - Livetencity
0,3
%
| - | - | 10 501 | 0,3 % | - |
Oncology - Exkivity
0,1
%
| - | - | 3 732 | 0,1 % | - |
Gastroenterology - Alofisel
0,1
%
| 1 843 | 0,1 % | 2 725 | 0,1 % | +47,86% |
Verkoop per regio
| JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
United States
52,2
%
| 1 714 421 | 48,0 % | 2 103 772 | 52,2 % | +22,71% |
Europe and Canada
20,9
%
| 739 168 | 20,7 % | 842 668 | 20,9 % | +14,00% |
Japan
12,7
%
| 658 983 | 18,5 % | 512 043 | 12,7 % | -22,30% |
Asia
5,6
%
| 196 964 | 5,5 % | 225 007 | 5,6 % | +14,24% |
Latin America
4,0
%
| 128 467 | 3,6 % | 160 375 | 4,0 % | +24,84% |
Other
2,4
%
| 68 945 | 1,9 % | 95 182 | 2,4 % | +38,05% |
Russia / Commonwealth of Independent States
2,2
%
| 62 057 | 1,7 % | 88 431 | 2,2 % | +42,50% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01-04-14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01-02-22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01-01-12 |
| Chief Tech/Sci/R&D Officer | 69 | 01-04-15 | |
Andrew Plump
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-02-15 |
Norimasa Takeda
CMP | Compliance Officer | - | - |
| Director/Board Member | 53 | 01-01-15 | |
Haruhiko Hirate
IRO | Public Communications Contact | - | - |
Takashi Okubo
IRO | Public Communications Contact | - | - |
| Investor Relations Contact | - | 01-06-11 |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
| Director/Board Member | 71 | 01-06-16 | |
Ian Clark
BRD | Director/Board Member | 62 | 01-01-19 |
Steven Gillis
BRD | Director/Board Member | 71 | 01-01-19 |
John Maraganore
BRD | Director/Board Member | 60 | 01-06-22 |
Emiko Higashi
BRD | Director/Board Member | 64 | 01-06-16 |
Michel Orsinger
BRD | Director/Board Member | 66 | 01-06-16 |
Christophe Weber
CEO | Chief Executive Officer | 57 | 01-04-14 |
| Director/Board Member | 53 | 01-01-15 | |
Kimberly Reed
BRD | Director/Board Member | 53 | 01-06-22 |
Miki Tsusaka
BRD | Director/Board Member | 61 | 01-04-23 |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 0 | 1 582 418 725 | 1 568 501 201 ( 99,12 %) | 13 405 261 ( 0,8471 %) | 99,12 % |
Participaties
| Naam | Aandelen | % | Totale waarde |
|---|---|---|---|
| 7 511 300 | 0.47% | 199 463 248 $ | |
HILLEVAX, INC. 13.52% | 6 724 000 | 13.52% | 81 629 360 $ |
DENALI THERAPEUTICS INC. 2.96% | 4 214 559 | 2.96% | 78 222 215 $ |
| 2 204 000 | 7.21% | 33 085 588 $ | |
OVID THERAPEUTICS INC. 12.38% | 8 781 996 | 12.38% | 26 872 908 $ |
| 2 790 480 | 4.77% | 26 286 322 $ | |
WAVE LIFE SCIENCES LTD. 0.90% | 1 096 892 | 0.90% | 6 778 793 $ |
NOILE-IMMUNE BIOTECH INC. 18.76% | 8 119 800 | 18.76% | 6 768 828 $ |
Bedrijfsgegevens
Takeda Pharmaceutical Co., Ltd.
4-1-1 Dosho-machi Chuo-Ku
540-8645, Osaka
+81 3 3278 2111
http://www.takeda.co.jp
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. |
Financial Conglomerates
|
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. |
Pharmaceuticals: Major
|
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Takeda Austria GmbH
 Takeda Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Austria GmbH engages in research and development of pharmaceutical products. The company is based in Linz, Austria. Kirsten Detrick has been the CEO of the Austrian company since 2016. |
Miscellaneous Commercial Services
|
Takeda GmbH
 Takeda GmbH Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Konstanz, Germany. The CEOs are Wolfgang Eck, Uwe Hoffmeister, Roland Kurney. The company was founded in 1873. |
Pharmaceuticals: Major
|
Takeda Manufacturing Austria AG
 Takeda Manufacturing Austria AG Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda Manufacturing Austria AG manufactures and supplies vital medicines and medical devices. The company is based in Vienna, Austria. |
Pharmaceuticals: Major
|
Shire Ireland Finance Trading Ltd.
| |
Shire Biotech India Pvt Ltd.
| |
Shire Biotech UK Holdings Ltd.
 Shire Biotech UK Holdings Ltd. Financial ConglomeratesFinance Part of Takeda Pharmaceutical Co., Ltd., Shire Biotech UK Holdings Ltd. is an investment holding company. Shire Biotech UK Holdings Ltd. is based in London, UK. Founded in 2017, Shire Biotech UK Holdings functions as an investment holding company. |
Financial Conglomerates
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +51,99% | 798 mld. | |
| -5,72% | 356 mld. | |
| +18,94% | 328 mld. | |
| +11,07% | 304 mld. | |
| +16,96% | 244 mld. | |
| +2,25% | 227 mld. | |
| +11,15% | 216 mld. | |
| +7,59% | 166 mld. | |
| -3,65% | 157 mld. |
- Beurs
- Aandelen
- Koers 4502
- Koers TKD
- Onderneming Takeda Pharmaceutical Company Limited
